A	B	C
1	Main
2		Brand Name	Risperdal Consta
3		Generic Name	risperidone
4		Administration	q2w IM injection by physician. Must give with oral medication at initiation.
5		Economics	J&J, 2.5% royalty and manufacturing revenue (7% mark up?).
6		Approved	10/29/2003 in the US.
7		Competition	Invega Sustenna (qm), Zyprexa Adhedra
8			Sustenna approval path in Europe/Japan?
9		History	Phase I started in 1996.
10		IP	Main Risperdal patent expired 6/29/08.
11			6110503 expires in 2017 and is an ALKS Medisorb patent.
12			7547452 2014
13			6667061 2020
14			6596316 2018
15			6403114 2017
16			6379703 2018
17			6368632 2014
18			6194006 2019
19			6110921 2014
20			5965168 2014
21			5916598 2017
22			5792477 2017
23			5688801 2014
24		Cost	$3k, $6k and $12k annually for low- mid- and high-dose. Sustenna more expensive.
25		RX	Sustenna 410 scripts 11/6/09, 6% of combined drugs.
26		Papers	Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Citrome. IJCP 2009.
27			Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia. Mohamed et al. Psychiatr Q 2009. - Demonstrates compliance may not be increased with Consta.
28		Clinical Trials
29			Phase III Consta vs Sustenna n=700 90-day
30
31			Phase III Consta vs Sustenna n=452 in China 90-day
32
33			Phase III Consta vs Sustenna n=748 360-day
34
35			Phase II Consta vs Sustenna - to be reported at ACNP???
36			150mg vs prior 50mg initiation dose